Larissa Heart Failure Risk Score and Mode of Death in Acute Heart Failure: Insights from REALITY-AHF

Patients with heart failure (HF) patients may die either suddenly (sudden cardiac death/SCD) or progressively from pump failure. The heightened risk of SCD in patients with HF may expedite important decisions about medications or devices. We used the Larissa Heart Failure Risk Score (LHFRS), a validated risk model for all-cause mortality and HF rehospitalization, to investigate the mode of death in 1363 patients enrolled in the Registry Focused on Very Early Presentation and Treatment in Emergency Department of Acute Heart Failure (REALITY-AHF). Cumulative incidence curves were generated using a Fine–Gray competing risk regression, with deaths that were not due to the cause of death of interest as a competing risk. Likewise, the Fine–Gray competing risk regression analysis was used to evaluate the association between each variable and the incidence of each cause of death. The AHEAD score, a well-validated HF risk score ranging from 0 to 5 (atrial fibrillation, anemia, age, renal dysfunction, and diabetes mellitus), was used for the risk adjustment. Patients with LHFRS 2–4 exhibited a significantly higher risk of SCD (HR hazard ratio adjusted for AHEAD score 3.15, 95% confidence interval (CI) (1.30–7.65), p = 0.011) and HF death (adjusted HR for AHEAD score 1.48, 95% CI (1.04–2.09), p = 0.03), compared to those with LHFRS 0,1. Regarding cardiovascular death, patients with higher LHFRS had significantly increased risk compared to those with lower LHFRS (HR 1.44 adjusted for AHEAD score, 95% CI (1.09–1.91), p = 0.01). Lastly, patients with higher LHFRS exhibited a similar risk of non-cardiovascular death compared to those with lower LHFRS (HR 1.44 adjusted for AHEAD score, 95% CI (0.95–2.19), p = 0.087). In conclusion, LHFRS was associated independently with the mode of death in a prospective cohort of hospitalized HF patients.

[1]  W. Whang,et al.  SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: Meta‐analysis of randomized clinical trials , 2023, Journal of cardiovascular electrophysiology.

[2]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.

[3]  G. Sinagra,et al.  [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.

[4]  A. Konishi,et al.  Efficacy of Renin-angiotensin-aldosterone-system inhibitors for heart failure with preserved ejection fraction and left ventricular hypertrophy -from the KUNIUMI Registry Acute Cohort. , 2021, Journal of cardiology.

[5]  K. Kinugawa,et al.  Interventional heart failure therapy: A new concept fighting against heart failure. , 2021, Journal of cardiology.

[6]  Akshay S. Desai,et al.  Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial , 2021, Circulation. Heart failure.

[7]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[8]  V. Roger Epidemiology of Heart Failure , 2021, Circulation research.

[9]  Akshay S. Desai,et al.  Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM‐HF analysis , 2021, European journal of heart failure.

[10]  F. Veglia,et al.  The MECKI score initiative: Development and state of the art , 2020, European journal of preventive cardiology.

[11]  P. Ponikowski,et al.  Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2. , 2020, JACC. Heart failure.

[12]  Akshay S. Desai,et al.  Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. , 2020, JACC. Heart failure.

[13]  J. McMurray,et al.  Risk stratification scores for patients with acute heart failure in the Emergency Department: A systematic review , 2020, European heart journal. Acute cardiovascular care.

[14]  F. Rutten,et al.  Epidemiology of heart failure , 2020, European journal of heart failure.

[15]  F. Triposkiadis,et al.  Validation of the Larissa Heart Failure Risk Score for risk stratification in acute heart failure. , 2019, International journal of cardiology.

[16]  N. Kagiyama,et al.  The time-to-treatment concept in acute heart failure: Lessons and implications from REALITY-AHF , 2018, Anatolian journal of cardiology.

[17]  W. Tang,et al.  Impact of early treatment with intravenous vasodilators and blood pressure reduction in acute heart failure , 2018, Open Heart.

[18]  A. Mebazaa,et al.  Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. , 2018, JACC. Heart failure.

[19]  M. Kattan,et al.  Larissa Heart Failure Risk Score: a proposed simple score for risk stratification in chronic heart failure , 2018, European journal of heart failure.

[20]  R. Matsukawa,et al.  Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure. , 2017, Journal of the American College of Cardiology.

[21]  Wen-Chung Yu,et al.  Performance of AHEAD Score in an Asian Cohort of Acute Heart Failure With Either Preserved or Reduced Left Ventricular Systolic Function , 2017, Journal of the American Heart Association.

[22]  J. Butler,et al.  A simple score for early risk stratification in acute heart failure. , 2017, International journal of cardiology.

[23]  Hsien-Yen Chang,et al.  Relationship between Early Physician Follow-Up and 30-Day Readmission after Acute Myocardial Infarction and Heart Failure , 2017, PloS one.

[24]  G. Fonarow,et al.  Epidemiology and aetiology of heart failure , 2016, Nature Reviews Cardiology.

[25]  Sanjiv J. Shah,et al.  Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy? , 2016, Heart Failure Reviews.

[26]  W. Shimizu,et al.  New scoring system (APACHE-HF) for predicting adverse outcomes in patients with acute heart failure: evaluation of the APACHE II and Modified APACHE II scoring systems. , 2014, Journal of cardiology.

[27]  F. Oliva,et al.  The ADHF/NT-proBNP risk score to predict 1-year mortality in hospitalized patients with advanced decompensated heart failure. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[28]  S. Solomon,et al.  Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved , 2014, European journal of heart failure.

[29]  F. Oliva,et al.  Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score. , 2013, International journal of cardiology.

[30]  G. Parati,et al.  Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: a multiparametric approach to heart failure prognosis. , 2013, International journal of cardiology.

[31]  C. O'connor,et al.  Association between bilirubin and mode of death in severe systolic heart failure. , 2013, The American journal of cardiology.

[32]  V. Hasselblad,et al.  Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. , 2010, Journal of the American College of Cardiology.

[33]  C. O'connor,et al.  Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). , 2008, American heart journal.

[34]  D. Mozaffarian,et al.  Prediction of Mode of Death in Heart Failure: The Seattle Heart Failure Model , 2007, Circulation.

[35]  A. Mebazaa,et al.  AHEAD score--Long-term risk classification in acute heart failure. , 2016, International journal of cardiology.